A Phase 1 interventional study of P03277 in Renal Insufficiency and Healthy Volunteers, sponsored by Guerbet. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-22.
Sponsored by Guerbet · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, non-randomized, successive cohorts design, multicenter, single dose phase I study.
The primary objectives are:
A full range design including the different degrees of renal impairment and healthy volunteers used as reference has been chosen.
Enrolment will be successive starting with both healthy volunteers (cohort 1) and patients with mild renal impairment (cohort 2), then patients with moderate renal impairment (cohort 3), then patients with severe renal impairment (cohort 4) to end with patients with end stage renal disease (cohort 5). Pharmacokinetics and safety profiles following the confinement period will be reviewed per each successive cohort by a Data Monitoring Committee before starting recruitment of patients in the next cohort. Cohorts 1 and 2 will be recruited in parallel and Data Monitoring Committee review will start after the completion of these first two cohorts.
1,412 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
This study's enrollment of 40 is close to the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
For all subjects:
For healthy volunteers / cohort 1:
Healthy volunteer with stable normal renal function defined with an absolute value of ≥ 90 mL/min based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements
For patients with renal impairment / cohorts 2 to 5:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
Drug: P03277
P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
Drug: P03277
P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
Drug: P03277
P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
Drug: P03277
P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
Drug: P03277
Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
Also known as: gadopiclenol
AUC
AUC: area under the plasma concentration curve. Blood samples will be collected.
Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)
Cmax
Cmax: peak concentration. Blood samples will be collected.
Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)
t1/2
t1/2: terminal half-life. Blood samples will be collected.
Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)
CLT
CLT: total clearance. Blood samples will be collected.
Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)
Ae
Ae: amount excreted. Urine samples will be collected.
Time frame: Prior to P03277 administration and during the intervals 0-6, 6-24, 24-48 hours for all cohorts + during 48-72 and 72-96 hours intervals for cohorts 2-3-4, 96-120 hours interval for cohorts 3-4, 120-144 hours and 144-168 hours intervals for cohort 4
Relative amount of eliminated P03277 in blood
This outcome will be assessed for cohort 5 only. Venous blood samples will be collected at each session of hemodialysis.
Time frame: Just before the start of the session and at 30, 90 minutes and 4 hours after the start of the session.
Clearance of P03277
This outcome will be assessed for cohort 5 only and at the first hemodialysis only. Arterial and venous blood samples will be collected.
Time frame: Just before the start of the session and at 30 and 90 minutes after the start of the session.
Dialysis clearance of P03277
This outcome will be assessed for cohort 5 only. Venous blood and dialysate samples will be collected at each session of hemodialysis.
Time frame: Just before the start of the session and at 30, 90 minutes and 4 hours after the start of the session.
P03277concentration in blood (long-term)
Blood samples will be collected.
Time frame: At 1, 3 and 6 months after P03277 administration
P03277 concentration in urine (long-term)
Urine samples will be collected.
Time frame: At 1, 3 and 6 months after P03277 administration
Ran from Oct 2017 to primary completion in Feb 2019, 15 months.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 15 months is above that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadopiclenol